Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time

Objectives We aimed to evaluate the effects of methotrexate (MTX) comedication added to biological disease-modifying antirheumatic drugs (bDMARD) on disease activity measures in patients with rheumatoid arthritis (RA) in routine care. Methods Patients with RA on treatment with either bDMARDs or conv...

ver descrição completa

Detalhes bibliográficos
Autor principal: Boone, Niels W. (author)
Outros Autores: Sepriano, Alexandre (author), Van Der Kuy, Paul Hugo (author), Janknegt, Rob (author), Peeters, Ralph (author), Landewé, Robert B.M. (author)
Formato: article
Idioma:eng
Publicado em: 2019
Assuntos:
DAS28
DMARDs (biologic)
methotrexate
patient reported outcome measure (PROM)
rheumatoid arthritis
Rheumatology
Immunology and Allergy
Immunology
Texto completo:https://doi.org/10.1136/rmdopen-2018-000836
País:Portugal
Oai:oai:run.unl.pt:10362/60028

Texto Completo

https://doi.org/10.1136/rmdopen-2018-000836

Registos relacionados